Lisinopril - Teva tablets 20mg, No. 30

Name: Lisinopril - Teva tablets 20mg, No. 30
SKU: BIDL3179757
Price: 18.43 USD
Availability: InStock

Be the first to review this product

Special Price $18.43 Regular Price $27.00

In stock

SKU

BIDL3179757

368.6 Reward Points will be used to purchase this product

Expiration Date: 05/2027

Russian Pharmacy name:

Лизиноприл - Тева таблетки 20мг, №30

Skip to the end of the images gallery

Skip to the beginning of the images gallery

Details

Lisinopril - Teva tablets 20mg, No. 30

- arterial hypertension

- chronic heart failure (as part of complex therapy with diuretics and cardiac glycosides)

- acute myocardial infarction in patients with stable hemodynamics without signs of renal dysfunction.

Arterial hypertension :

Treatment should start at 5 mg daily in the morning. The dose should be adjusted in such a way as to provide optimal control of the blood pressure level. The time interval between dose increases should be at least 3 weeks. The usual maintenance dose is 10Ц20 mg of lisinopril once a day, with a maximum daily dose of 40 mg once a day.

Heart failure :

Lisinopril-Teva is prescribed in addition to the existing therapy with diuretics and digitalis. The starting dose is 2.5 mg in the morning. The maintenance dose should be set in increments of 2.5 mg at intervals of 2-4 weeks. The usual maintenance dose is 5Ц20 mg once a day. Do not exceed the maximum dose of 35 mg lisinopril / day.

Acute myocardial infarction in patients with stable hemodynamics :

Treatment with Lisinopril-Teva can begin within 24 hours after the onset of symptoms, provided that hemodynamics are stable (systolic pressure is more than 100 mm Hg, without signs of renal dysfunction), in addition to standard heart attack therapy (thrombolytic drugs, acetylsalicylic acid, beta-blockers, nitrates). The initial dose is 5 mg, after 24 hours - another 5 mg, after 48 hours - 10 mg. Then the dose is 10 mg of lisinopril 1 time per day.

Patients with low systolic pressure (? 120 mm Hg) before starting therapy or within the first 3 days after a heart attack should receive a lower therapeutic dose for treatment - 2.5 mg of Lisinopril-Teva. If the systolic pressure is less than 90 mm Hg. Art. more than 1 hour, you should abandon Lisinopril-Teva.

Treatment should continue for 6 weeks. The minimum maintenance dose is 5 mg per day. Patients with symptoms of heart failure should continue to be treated with Lisinopril-Teva. The drug can be given simultaneously with nitroglycerin (intravenously or as a skin patch).

In myocardial infarction, lisinopril should be given in addition to the usual standard therapy (thrombolytic agents, acetylsalicylic acid, beta-blockers), preferably together with nitrates.

Elderly patients :

In elderly patients, the dosage should be adjusted based on the creatinine level (to assess renal function), which is calculated using the Cockcroft formula:

Creatinine clearance =

(140 - age)? body weight (kg)

0.814? serum creatinine concentration (?mol / l)

(For women, the result obtained using this formula must be multiplied by 0.85).

Dosage in patients with moderately limited renal function (creatinine clearance 30 - 70 ml / min) :

The initial dose is 2.5 mg of the drug in the morning, the maintenance dose is 5-10 mg per day. Do not exceed the maximum dose of 20 mg of lisinopril per day.

Lisinopril-Teva can be taken with or without food, but with sufficient fluid, once a day, preferably at the same time.

One tablet contains:

active substance - lisinopril dihydrate 21.78 mg, equivalent to anhydrous lisinopril 20 mg,

excipients : mannitol, calcium hydrogen phosphate dihydrate, pregelatinized starch, PB-24823 dye, croscarmellose sodium, magnesium stearate.

- increased susceptibility to the active substance or other ACE inhibitors or one of the excipients

- renal artery stenosis (bilateral or unilateral with one kidney)

- a history of angioedema due to previous therapy with an ACE inhibitor and hereditary / spontaneous angioedema

- simultaneous use of lisinopril with products containing aliskiren in patients with diabetes mellitus or renal failure (GFR <60 ml / min / 1.73 m2)

- severe renal dysfunction (creatinine clearance <30 ml / min).

- hemodynamically relevant stenosis of the aorta or mitral valve or hypertrophic cardiomyopathy

- acute myocardial infarction in patients with unstable hemodynamics

- systolic pressure? 100 mmHg Art. before starting treatment

- lactation

- pregnancy and lactation period

- cardiogenic shock

- children under 18 years old

- primary hyperaldosteronism

- condition after kidney transplantation

Tradename

Lisinopril-Teva

International non-proprietary name

Lisinopril

Dosage form

Tablets 5 mg, 10 mg, 20 mg

Composition:

One tablet contains:

active substance - lisinopril dihydrate 21.78 mg, equivalent to anhydrous lisinopril 20 mg,

excipients : mannitol, calcium hydrogen phosphate dihydrate, pregelatinized starch, PB-24823 dye, croscarmellose sodium, magnesium stearate.

Description

Tablets are white, round, biconvex, scored on one side (for a dosage of 5 mg).

Tablets are light pink, round, biconvex, with a score on one side (for a dosage of 10 mg).

Pink tablets, round, biconvex with a scored on one side (for a dosage of 20 mg).

Pharmacotherapeutic group

Drugs affecting the renin-angiotensin system. Angiotensin-converting enzyme (ACF) inhibitors. Lisinopril.

Pharmacological properties

Pharmacokinetics

The maximum plasma concentration is reached approximately 7 hours after oral administration. Food intake does not affect the rate of absorption of lisinopril. Lisinopril does not bind to blood plasma proteins. The absorbed biologically active substance is completely and unchanged excreted through the kidneys. The effective half-life was 12.6 hours. Lisinopril crosses the placenta.

Pharmacodynamics

Lisinopril-Teva is an angiotensin converting enzyme (ACE inhibitor) inhibitor. The suppression of ACE leads to a reduced formation of angiotensin II (with a vasoconstrictor effect) and to a decrease in the secretion of aldosterone. Lisinopril-Teva also blocks the breakdown of bradykinin, a powerful vasodepressor peptide. As a result, it lowers blood pressure, total peripheral vascular resistance, pre- and afterload on the heart, increases minute volume, cardiac output and increases myocardial tolerance to stress and improves blood supply to the ischemic myocardium. In patients with acute myocardial infarction, Lisinopril-Teva, together with nitrates, reduces the formation of left ventricular dysfunction or heart failure.

Indications

- arterial hypertension

- chronic heart failure (as part of complex therapy with diuretics and cardiac glycosides)

- acute myocardial infarction in patients with stable hemodynamics without signs of renal dysfunction.

Method of administration and dosage

Arterial hypertension :

Heart failure :

Acute myocardial infarction in patients with stable hemodynamics :

Patients with low systolic pressure (120 mm Hg) before starting therapy or within the first 3 days after a heart attack should receive a lower therapeutic dose for treatment - 2.5 mg of Lisinopril-Teva. If the systolic pressure is less than 90 mm Hg. Art. more than 1 hour, you should abandon Lisinopril-Teva.

In myocardial infarction, lisinopril should be given in addition to the usual standard therapy (thrombolytic agents, acetylsalicylic acid, beta-blockers), preferably together with nitrates.

Elderly patients :

In elderly patients, the dosage should be adjusted based on the creatinine level (to assess renal function), which is calculated using the Cockcroft formula.

Dosage in patients with moderately limited renal function (creatinine clearance 30 - 70 ml / min) :

The initial dose is 2.5 mg of the drug in the morning, the maintenance dose is 5-10 mg per day. Do not exceed the maximum dose of 20 mg of lisinopril per day.

Lisinopril-Teva can be taken with or without food, but with sufficient fluid, once a day, preferably at the same time.

Side effects

Sometimes

- headaches, dizziness, feeling of weakness, visual disturbances, fatigue

- dry cough, sore throat

- nausea, loss of appetite, diarrhea, constipation, vomiting

- allergic rash

Seldom

- stunned consciousness, depression, sleep disturbances, tinnitus, disturbances in the sense of balance, nervousness, changes in taste

- peripheral neuropathy with paresthesias, muscle cramps, hot flush, sweating

- shortness of breath, bronchospasm, allergic alveolitis

- tachycardia, cardiac arrhythmias, cardiogenic shock, chest pain, orthostatic hypotension

- cholestatic jaundice, proteinuria and increased serum bilirubin and liver enzymes

- anemia, thrombocytopenia, neutropenia, eosinophilia, in some cases agranulocytosis or pancytopenia; an increase in the concentration of urea, creatinine and potassium and a decrease in the concentration of sodium in the blood serum (in patients with impaired renal function)

- in some cases: hemolytic anemia in patients with a significant deficiency of glucose-3-phosphate dehydrogenase

- pruritus, urticaria, angioedema, pemphigus, erythema multiforme, exfoliative dermatitis, Stevens-Johnson syndrome, toxic epidermal necrosis, psoriasis, photosensitivity, alopecia, onycholysis

- Raynaud's syndrome

- impotence

Rarely

- arthralgia

Contraindications